Currently, the compound AZD4547 is being studied in several Phase I and II clinical trials, as shown in a study conducted by Andre et al. [166] in patients with recurrent IDH wild-type gliomas with FGFR1–TACC1 or FGFR3–TACC3 fusions. This evidence concerns the gene FGFR3 and glioma.